KOL Insight

Datamonitor Healthcare Hepatocellular Carcinoma (HCC) KOL Interview – US, South #2

This interview provides a thorough description of hepatocellular carcinoma (HCC) treatment in the US. All targeted therapies available for HCC treatment are discussed, as well as a discussion of Phase III pipeline drugs and the potential impact these therapies would have if they gain approval.

Datamonitor Healthcare HIV KOL Interview – UK

A UK key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

Follicular Lymphoma KOL Interview – Germany

This interview with a German KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for follicular lymphoma. Future trends and unmet needs are also discussed. Key drug classes highlighted include anti-CD20 antibodies (Rituxan and Gazyva), immunomodulators (Revlimid), autologous CAR-T therapies (Yescarta and Kymriah), CD20 x CD3 bispecifics (Lunsumio), BTK inhibitors (Imbruvica and Brukinsa), EZH2 inhibitors (Tazverik), PI3 kinase inhibitors (Copiktra, Zydelig, Aliqopa, and zandelisib), and anti-CD19 antibodies (Monjuvi).

Acne Prescribing Practices Pulse Survey

We performed a survey of 10 dermatologists currently practicing in the US to gauge

prescribing practices for the treatment of acne.